Subscribe to RSS
Long-Term Seizures Outcome in Juvenile Myoclonic Epilepsy (JME): A Retrospective Cohort Study in an Indian PopulationFunding None.
Objectives Juvenile myoclonic epilepsy (JME) is the most prevalent form of generalized epilepsy in the community. Though the response to medication is good in most patients, long-term medication usage may lead to poor compliance, side effects, and other epilepsy-related social issues. The aim of this study was to describe the demography, clinical features, and therapeutic response in patients with JME who have had at least 10 years of duration of epilepsy.
Materials and Methods A retrospective study of 56 patients (M:F=26:30; mean age: 14.5 ± 5.1 years) with JME attending neurological services in a tertiary care neurological center in South India with more than 10 years disease duration was performed.
Results All patients had myoclonic jerks, 94% had generalized tonic–clonic seizure, and only 7.1% had features of absence seizures. Seizures were controlled in 60% of cases at the end of 10 years of epilepsy. Thirty-eight patients (67.8%) were on valproate. Control of seizures at the end of the first and fifth years of epilepsy, frequent myoclonic jerks at the onset, and treatment with valproate in the first year of disease resulted in controlled seizures at the end of 10 years. No patient was off medications at the end of 10 years of epilepsy or at the last follow-up.
Conclusion About 40% of our patients continued to have seizures even 10 years after the onset of epilepsy. Regular and long-term medication may be required in JME. Early control of seizures, response to valproate, and frequent myoclonia at onset were found to confer better prognosis.
30 July 2021 (online)
© 2021. Indian Society of Epilepsy. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 1 Kasteleijn-Nolst Trenité DGA, de Weerd A, Beniczky S. Chronodependency and provocative factors in juvenile myoclonic epilepsy. Epilepsy Behav 2013; 28 (Suppl. 01) S25-S29
- 2 Chakravarty A, Mukherjee A, Roy D. Observations on juvenile myoclonic epilepsy amongst ethnic Bengalees in West Bengal–an Eastern Indian State. Seizure 2007; 16 (02) 134-141
- 3 Murthy JMK, Rao CM, Meena AK. Clinical observations of juvenile myoclonic epilepsy in 131 patients: a study in South India. Seizure 1998; 7 (01) 43-47
- 4 Vijai J, Cherian PJ, Stlaja PN, Anand A, Radhakrishnan K. Clinical characteristics of a South Indian cohort of juvenile myoclonic epilepsy probands. Seizure 2003; 12 (07) 490-496
- 5 Panayiotopoulos CP, Obeid T, Tahan AR. Juvenile myoclonic epilepsy: a 5-year prospective study. Epilepsia 1994; 35 (02) 285-296
- 6 Senf P, Schmitz B, Holtkamp M, Janz D. Prognosis of juvenile myoclonic epilepsy 45 years after onset: seizure outcome and predictors. Neurology 2013; 81 (24) 2128-2133
- 7 Holtkamp M, Senf P, Kirschbaum A, Janz D. Psychosocial long-term outcome in juvenile myoclonic epilepsy. Epilepsia 2014; 55 (11) 1732-1738
- 8 Hernández-Vanegas LE, Jara-Prado A, Ochoa A. et al High-dose versus low-dose valproate for the treatment of juvenile myoclonic epilepsy: going from low to high. Epilepsy Behav 2016; 61: 34-40
- 9 Calleja S, Salas-Puig J, Ribacoba R, Lahoz CH. Evolution of juvenile myoclonic epilepsy treated from the outset with sodium valproate. Seizure 2001; 10 (06) 424-427
- 10 DiLiberti JH, Farndon PA, Dennis NR, Curry CJR. The fetal valproate syndrome. Am J Med Genet 1984; 19 (03) 473-481
- 11 Tomson T, Battino D, Bonizzoni E. et al EURAP Study Group. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology 2015; 85 (10) 866-872
- 12 Viswanathan LG, Satishchandra P, Bhimani BC. et al Polycystic ovary syndrome in patients on antiepileptic drugs. Ann Indian Acad Neurol 2016; 19 (03) 339-343
- 13 Serafini A, Gerard E, Genton P, Crespel A, Gelisse P. Treatment of juvenile myoclonic epilepsy in patients of child-bearing potential. CNS Drugs 2019; 33 (03) 195-208
- 14 Holtkamp M, Kowski AB, Merkle H, Janz D. Long-term outcome in epilepsy with grand mal on awakening: forty years of follow-up. Ann Neurol 2014; 75 (02) 298-302
- 15 Geithner J, Schneider F, Wang Z. et al Predictors for long-term seizure outcome in juvenile myoclonic epilepsy: 25-63 years of follow-up. Epilepsia 2012; 53 (08) 1379-1386
- 16 Höfler J, Unterberger I, Dobesberger J, Kuchukhidze G, Walser G, Trinka E. Seizure outcome in 175 patients with juvenile myoclonic epilepsy–a long-term observational study. Epilepsy Res 2014; 108 (10) 1817-1824
- 17 Harden C. Juvenile myoclonic epilepsy-what does the future look like?. Epilepsy Curr 2014; 14 (03) 150-151
- 18 Jain S, Padma MV, Maheshwari MC. Occurrence of only myoclonic jerks in juvenile myoclonic epilepsy. Acta Neurol Scand 1997; 95 (05) 263-267
- 19 Stevelink R, Koeleman BPC, Sander JW, Jansen FE, Braun KPJ. Refractory juvenile myoclonic epilepsy: a meta-analysis of prevalence and risk factors. Eur J Neurol 2019; 26 (06) 856-864
- 20 Guaranha MSB, Filho GM de A, Lin K, Guilhoto LMFF, Caboclo LOSF, Yacubian EMT. Prognosis of juvenile myoclonic epilepsy is related to endophenotypes. Seizure 2011; 20 (01) 42-48
- 21 Canevini MP, Mai R, Di Marco C. et al Juvenile myoclonic epilepsy of Janz: clinical observations in 60 patients. Seizure 1992; 1 (04) 291-298
- 22 Seneviratne U, Cook M, D’Souza W. The prognosis of idiopathic generalized epilepsy. Epilepsia 2012; 53 (12) 2079-2090
- 23 Raju PK, Satishchandra P, Nayak S, Iyer V, Sinha S, Anand A. Microtubule-associated defects caused by EFHC1 mutations in juvenile myoclonic epilepsy. Hum Mutat 2017; 38 (07) 816-826
- 24 Cavalleri GL, Walley NM, Soranzo N. et al A multicenter study of BRD2 as a risk factor for juvenile myoclonic epilepsy. Epilepsia 2007; 48 (04) 706-712
- 25 Vijai J, Kapoor A, Ravishankar HM. et al Genetic association analysis of KCNQ3 and juvenile myoclonic epilepsy in a South Indian population. Hum Genet 2003; 113 (05) 461-463
- 26 Kapoor A, Vijai J, Ravishankar HM, Satishchandra P, Radhakrishnan K, Anand A. Absence of GABRA1 Ala322Asp mutation in juvenile myoclonic epilepsy families from India. J Genet 2003; 82 (1-2) 17-21
- 27 von Podewils F, Kowoll V, Schroeder W. et al Predictive value of EFHC1 variants for the long-term seizure outcome in juvenile myoclonic epilepsy. Epilepsy Behav 2015; 44: 61-66